Portfolio News
As the centerpiece of this collaboration, both parties will engage in multi-dimensional collaboration around the research and development of drugs for treating autoimmune diseases, neurological disorders and other debilitating diseases, leveraging their respective strengths to establish a complete chain from preclinical research to clinical application. According to the cooperation agreement, the partnership will encompass five key areas:
·Joint Research: Both parties will integrate their respective expertise to conduct scientific research, including discovery research, target identification, and animal model development for autoimmune diseases, neurological disorders and other debilitating diseases. SYSU-IAS shall
provide laboratory facilities and experimental animals for joint research.
·Facility Resource Sharing: SinoMab will leverage laboratory resources established by
SYSU-IAS at the Shenzhen Futian International Biomedical Industry Park. The jointly
branded "SYSU-IAS-SinoMab Joint Laboratory" will provide advanced laboratory
support for collaborative R&D, effectively reducing research costs and enhancing
innovation efficiency.
·Full-Chain Technical Support: SYSU-IAS will deliver comprehensive support for
cooperative projects across the entire R&D workflow, including regulatory consulting,
coordination with regulatory authorities (including Hong Kong's Department of Health,
the U.S. Food and Drug Administration (FDA), China's National Medical Products
Administration, etc.), selection and deployment of clinical trial sites, and
organization/implementation of animal studies, ensuring efficient and compliant
advancement of research activities.
·Drug Development: SinoMab will select and provide at least one drug candidate for
IND filing and clinical development in China and the U.S., assuming full responsibility
for all stages of clinical development, including trial design, execution, and financial
investment.
·Training and Knowledge Exchange: The parties will promote training programs and
personnel exchanges to enhance R&D capabilities for the development of therapeutics
for autoimmune diseases, neurological disorders and other debilitating diseases, and
facilitate collaboration among SinoMab, SYSU-IAS, and the University of Oxford in
biomedical innovation research and commercialization of research outcomes.
This collaboration aims to synergize the strengths of both parties to accelerate innovative drug
development and global clinical translation of research outcomes. The collaboration will
adopt a project-driven approach, emphasizing on sharing laboratory resources and data, while
ensuring efficient communication to advance innovation and foster research collaboration in
clinical translation with the University of Oxford. Short-term objectives focus on validating
potential therapeutic targets, developing preclinical drug candidates that meet international
standards, establishing efficient collaboration processes, and enhancing R&D capabilities
aligned with global market requirements. Long-term aspirations are dedicated to advancing
drug candidates into clinical trials globally, building an innovative therapeutic pipeline
covering autoimmune diseases, neurological disorders and other debilitating diseases, and
ensuring innovative therapies that benefit global patients including those in underserved
markets through academic knowledge dissemination and commercialization strategy
formulation.
Dr. Leung Shui On, Chairman, Executive Director and Chief Executive Officer of
SinoMab, noted, "In the context of accelerating global biomedical innovation, individual
efforts can hardly meet current challenges. SinoMab has been deeply engaged in the field of
immunological disorder covering autoimmunity, neurological disorder and other debilitating
diseases for many years, and a number of its investigational drugs, including the global
first-in-class antibody SM17, which showed differentiating clinical efficacy for treating atopic
dermatitis, and SM03 (Suciraslimab), which have entered clinical stages with demonstrated
therapeutic effects for rheumatoid arthritis and systemic lupus erythematosus. The
collaboration with the Sun Yat-sen University Institute of Advanced Studies Hong Kong has
established a mutually beneficial framework. This partnership enables the Group to directly
access the Institute’s well-equipped laboratory facilities, valuable data resources, and animal
research support, including both primate and non-primate experiments, thereby driving
innovative drug development. At the same time, it will further enhance our capabilities in
target validation, preclinical research, and global regulatory submissions. These
advancements will accelerate the translation of innovative therapies from ‘laboratory to
patients, address unmet clinical needs, effectively promote business growth, and strengthen
our long-term competitive advantages."
Arepresentative from Sun Yat-sen University Institute of Advanced Studies Hong Kong
stated, "The Institute has always been committed to solving global medical challenges. This
collaboration with SinoMab is an alignment between scientific resources and industrial
capabilities. Our strengths in animal model construction, regulatory expertise, and shared
laboratory facilities will generate strong synergies with SinoMab’s proven track record in
antibody drug research and development, accelerating breakthroughs in the treatment of
autoimmune diseases — including those leading to neurological disorders and other refractory,
debilitating diseases."
